CLINICAL AND LABORATORY ASPECTS IN MULTIPLE MYELOMA (LITERATURE REVIEW)
Keywords:
myeloma, diagnosis, plasma cells, disease.Abstract
With myeloma, clinical manifestations appear, which are explained by the proliferation of myeloma cells in the bone marrow and the action of the immunoglobulins and free light chains produced by them. The updated criteria allow for early diagnosis and treatment prior to the development of end organ damage. As follows from the criteria, the diagnosis of multiple myeloma requires the presence of 10% or more plasma cells on bone marrow examination or the presence of a biopsy-proven plasmacytoma, plus one or more disorders due to the disease.
References
Bessmelsev SS 06/03/2013. Russia
James R.Berenson MD Institute for Myeloma and Bone Cancer Research Medical Review Oct 2021.
Qoʻzieva GZ, X. Ya. Karimov, AA Qayumov 2019 y.
Kurmar SK et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology // J Natl Compr Canc Netw. - 2017. - Vol. 15. No. 2. - P. 230-269.
Natural history of t(11,14) multiple myeloma|| Leukemia. -2018.-Vol.32, No.1. -P.131-138.
Neri, P. Genomic instability in multiple myeloma: mechanisms and therapeutic implications / P Neri, NJ Bahlis // Expert Opin Biol Ther. -2013, Jun. -V.13. -Suppl #1. -P. 69-82.
NiIBet al. Translocation t(11,14) (q13,q32) and genomic imbalances in multi-ethnic multiple myeloma patients. a Malaysian study || Hematol Rep.-2012.-Vol.4, No.3.-P.60-65.
Rajkumar SV: Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95:548–567, 2020.
Sive J, Cuthill K, Hunter H, Kazmi M, Pratt G, Smith D and on behalf of the British Society of Haematology: Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Brit J Haematol 193:245–268, 2021.
Suzuki K., Takahashi H. The epidemiology of multiple myeloma || Nihon Rinsho.- 2015.-Vol.73, No.1.-P.7-12.
